$1.37 and climbing. Stelfonta keeps kicking goals on social media. It's working and people can see it in posts from dog owners themselves. Stelfonta has recently won the coveted "Les Prix de l'Innovation Vétérinaire” among 16 shortlisted 2020 veterinary innovations. The jury found Stelfonta to be the most innovative product and was described as "a great therapeutic advance". See https://innovationveterinaire.com . There's also an interesting new scientific report in Nature (one of the world's most prestigious academic journals) regarding Tigilanol Tiglate and anti cancer activity. The article, based on TT study, suggests that potent antitumor activity observed with several of the epoxytiglianes arises from stimulation of PKC signaling and that results suggest a reassessment of the role of PKC in cancer may be necessary. It also mentions that "...recent results have potentially highlighted the recruitment of neutrophils following treatment as an important factor in TT efficacy. Therefore, the efficacy of the active epoxytiglianes may be due to the effects of the class on the innate immune system, in particular recruitment and activation of neutrophils, and warrants further investigation."
